DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB

DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB Stock

DE000VM5UQ23

Market Closed - Deutsche Boerse AG 14:04:17 2024-06-20 EDT
37.23 ^EUR	+0.92%

Current month	+2.62%
1 month	+2.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	06-20	BU
Bristol Myers: ex-CEO of Agilent joins Board of Directors	06-19	CF
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	06-18	BU
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	06-18	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-20	37.23	+0.92%
24-06-19	36.89	-0.46%
24-06-18	37.06	-0.05%
24-06-17	37.08	-0.38%
24-06-14	37.22	+0.49%

Delayed Quote Deutsche Boerse AG

Last update June 20, 2024 at 02:04 pm

More quotes

Static data

Product type	Certificats Discount
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Vontobel
WKN	VM5UQ2
ISIN	DE000VM5UQ23
Date issued	2023-11-22
Cap	40 $
Last trading day	Today
Maturity	Today (1 Days)
Parity	1 : 1
Emission price	35.22 €
Emission volume	N/A
Payment day	2024-06-28
Bonus	- €
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Discount (ask)	0.000000 %
Sideways yield	0.000000 %
Sideways yield pa	0.000000 %
Outperformance point	- $
Break even	0.000000 €
Highest since issue	37.23 €
Lowest since issue	34.52 €
Spread	-0.07 €
Spread %	0.19%
Distance Cap	1.04 $
Distance Cap %	+2.53%
Max. earning	-
Max. earning %	0.000000 %

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.04 USD

Average target price

53.19 USD

Spread / Average Target

+29.62%

Consensus